Elobixibat

Systematic (IUPAC) name
N-{(2R)-2-[({[3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylacetyl}glycine
Clinical data
Legal status	Investigational
Routes of administration	Oral
Identifiers
ATC code	None
PubChem	CID 9939892
ChemSpider	8115513
Chemical data
Formula	C36H45N3O7S2
Molar mass	695.89 g/mol
SMILES O=C(O)CNC(=O)[C@@H](c1ccccc1)NC(=O)COc4cc3c(N(c2ccccc2)CC(CS3(=O)=O)(CCCC)CCCC)cc4SC
InChI InChI=InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1 Key:XFLQIRAKKLNXRQ-UUWRZZSWSA-N

Elobixibat is an IBAT inhibitor,^[1] in clinical testing as of December 2012 for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C). It works by blocking the enterohepatic circulation of bile acids, increasing the bile acid concentration in the gut, which accelerates intestinal passage and softens the stool.

The drug was developed by Albireo AB, who licensed it to Ferring Pharmaceuticals for further development and marketing.^[2][3]

Albireo has partnered with Ajinomoto Pharmaceuticals, giving the Japan-based company the rights to further develop the drug and market it throughout Asia.^[4]

References

1. "INN for A3309 is ELOBIXIBAT". AlbireoPharma. Retrieved 5 December 2012.
2. H. Spreitzer (27 August 2012). "Neue Wirkstoffe – Elobixibat". Österreichische Apothekerzeitung (in German) (18/2012): 24.
3. "Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB" (Press release). Ferring Pharmaceuticals. 3 July 2012.
4. "Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixibat". Albireo. Retrieved 5 December 2012.